A review of the clinical efficacy of monoclonal antibody (mAb)-based therapies for relapsed/refractory multiple myeloma (RRMM)
The widespread use of daratumumab and isatuximab in first-line therapy and evolving roles of CAR T-cell therapies and bispecific antibodies are reshaping RRMM treatment. mAb/ADC-based regimens remain key options in this setting, offering practical, effective, and tolerable approaches for real-world practice. Ongoing research will inform individualized treatment choices and rational sequencing of therapies, with a need for immune-based biomarkers and biologic profiling to enable optimal, integrated use of mAbs, ADCs, CAR T-cell therapies, and bispecific antibodies to further improve outcomes for patients with RRMM.
Authors
- Clifton C. Mo (ORCID: https://orcid.org/0000-0001-8190-2484)
- Shonali Midha (ORCID: https://orcid.org/0000-0003-4948-5507)
- Jessica Croteau
- Shahrier Hossain (ORCID: https://orcid.org/0009-0004-6346-3376)
- Jacob P. Laubach (ORCID: https://orcid.org/0000-0001-7565-2052)
- Tarek H. Mouhieddine (ORCID: https://orcid.org/0000-0002-1190-5978)
- Taya Salman
- Poy Theprungsirikul (ORCID: https://orcid.org/0000-0001-9501-4218)
- Taylor Nicholson
- Ying Liu (ORCID: https://orcid.org/0000-0003-3672-9621)
- Omar Nadeem
- Natalie Kazierad
- Ji Hyun Lee
- Paul G. Richardson
Institutions
- Harvard University (US)
- Dong-A University (KR)
Publication Details
- Journal
- Expert Opinion on Biological Therapy
- Published
- 2026-03-17
- DOI
- https://doi.org/10.1080/14712598.2026.2646947
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00